CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies avail...
Phase 3
New Braunfels, Texas, United States and 35 other locations
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd...
Phase 2
Austin, Texas, United States and 62 other locations
ovarian function in premenopausal women with HR+, HER2-negative breast cancer and men with HR+ breast cancer. The...
Phase 3
New Braunfels, Texas, United States and 17 other locations
growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine ...
Phase 3
Austin, Texas, United States and 294 other locations
treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and arom...
Phase 3
Austin, Texas, United States and 217 other locations
ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The study will also aim to assess the safety of TOL2 ...
Phase 3
Austin, Texas, United States and 69 other locations
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer...
Phase 3
Austin, Texas, United States and 805 other locations
doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlik...
Phase 3
Round Rock, Texas, United States and 240 other locations
receptor-low/HER2-negative breast cancer....
Phase 3
Austin, Texas, United States and 351 other locations
adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurren...
Phase 3
Austin, Texas, United States and 734 other locations
Clinical trials
Research sites
Resources
Legal